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Research
Certain chemicals present in consumer 
 products and food can disrupt the action of 
steroidal androgens in fetal life, with irrevers­
ible consequences for later life stages. In the 
male rat, exposure to such chemicals during 
development leads to incomplete masculiniza­
tion and severe malformations of the reproduc­
tive organs (Christiansen et al. 2008; Welsh 
et al. 2008; Wilson et al. 2008). Because of 
their relevance to humans, the effects seen in 
laboratory animals have led to considerable 
concerns. Substances of interest, so­called anti­
androgens, include certain phthalates (widely 
used as plasticizers), a few pharma ceutical 
agents, and some fungicides. Phthalates have 
attracted signifi cant recent interest, with sev­
eral regulatory bodies currently engaged in risk 
assessments. As yet, these regulatory efforts 
have taken little account of realistic human 
exposures to several phthalates and other anti­
androgens simultaneously (Blount et al. 2000; 
Brock et al. 2002; Main et al. 2006; Marsee 
et al. 2006; Swan et al. 2005). With the aim of 
exploring the effects of combined exposure to 
anti androgens during gestation, we conducted 
large developmental toxicity mixture experi­
ments in the rat with the widely used plasticizer 
di(2­ethylhexyl) phthalate (DEHP), the fungi­
cides vinclozolin and prochloraz (present in 
certain food items), and the  pharmaceutical 
finasteride.
We chose to examine these anti androgens 
because they can disrupt male sexual differen­
tiation in different ways, by a variety of mecha­
nisms. In fetal life, testosterone is a key driver 
of the differentiation of the Wolffian duct sys­
tem into the vas deferens, epididymis, semi­
nal vesicles, and external genitalia. Phthalates 
with a certain ester side­chain length, such as 
DEHP, can lower testosterone levels by inter­
fering with the uptake of cholesterol precursors 
into fetal Leydig cells, where testicular andro­
gen production takes place (Foster et al. 1980). 
In the rat, malformations of internal reproduc­
tive organs (epididymis, testes) are the conse­
quence. Because dihydro testosterone (DHT) 
is derived from testosterone through enzymatic 
conversion by 5α­reductase, lower testosterone 
concentrations also affect the development of 
tissues that rely on DHT (prostate and exter­
nal genitalia). DHT is further required for the 
regression of nipple anlagen in male rats and 
for the growth of the perineum to produce 
the normal male anogenital distance (AGD), 
which is longer than in females (Imperato­
McGinley et al. 1985, 1986). Because of 
reduced DHT levels in the wake of suppressed 
testosterone synthesis, retained nipples and 
feminized AGDs are also seen in male rats 
exposed to phthalates in fetal life (Carruthers 
and Foster 2005; Foster 2006; Jarfelt et al. 
2005). Vinclozolin metabolites affect more 
directly the development of DHT­dependent 
tissues by antagonizing the androgen receptor 
(AR) (Gray et al. 1999; Hass et al. 2007; Wolf 
et al. 2000). In disrupting the enzymatic con­
version of testosterone to DHT through inhi­
bition of 5α­reductase (Bowman et al. 2003; 
Clark et al. 1990), the pharmaceutical finas­
teride induces an effect spectrum similar to 
that of AR antagonists. Finally, the fungicide 
prochloraz disrupts androgen action by inhib­
iting the conversion of progesterone to testos­
terone and by antagonizing the AR (Blystone 
et al. 2007; Laier et al. 2006; Noriega et al. 
2005; Vinggaard et al. 2002, 2005).
One goal of mixture toxicology is to 
antici pate the toxicities of untested mixtures 
of chemicals when only the effects of indi­
vidual components are known (Hermens et al. 
1984, 1985; Könemann 1980, 1981). A sec­
ond issue of relevance to regulatory toxicology 
concerns the question of mixture effects at 
low doses. A view that has persisted over the 
last 30 years is that combination effects do 
not occur when each chemical is present at 
doses equal to their no observed adverse effect 
levels (NOAELs) or lower [Committee on the 
Toxicity of Chemicals in Food, Consumer 
Products and the Environment (COT) 2002; 
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Background: By disrupting the action of androgens during gestation, certain chemicals present 
in food, consumer products, and the environment can induce irreversible demasculini zation and 
malformations of sex organs among male offspring. However, the con sequences of simultaneous 
exposure to such chemicals are not well described, especially when they exert their actions by differ-
ing molecular mechanisms.
oBjectives: To fill this gap, we investigated the effects of mixtures of a widely used plasticizer, 
di(2-ethylhexyl) phthalate (DEHP); two fungicides present in food, vinclozolin and prochloraz; 
and a pharmaceutical, finasteride, on landmarks of male sexual development in the rat, including 
changes in anogenital distance (AGD), retained nipples, sex organ weights, and malformations of 
genitalia. These chemicals were chosen because they disrupt androgen action with differing mecha-
nisms of action.
results: Strikingly, the effect of combined exposure to the selected chemicals on malformations 
of external sex organs was synergistic, and the observed responses were greater than would be pre-
dicted from the toxicities of the individual chemicals. In relation to other hallmarks of disrupted 
male sexual development, including changes in AGD, retained nipples, and sex organ weights, the 
combined effects were dose additive. When the four chemicals were combined at doses equal to no 
observed adverse effect levels estimated for nipple retention, significant reductions in AGD were 
observed in male offspring.
conclusions: Because unhindered androgen action is essential for human male development in 
fetal life, these findings are highly relevant to human risk assessment. Evaluations that ignore the 
possibility of combination effects may lead to considerable underestimations of risks associated with 
exposures to chemicals that disrupt male sexual differentiation.
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Safety (VKM) 2008]. This is thought to be the 
case with chemicals that act through different 
mechanisms, but not with agents that target 
similar molecular structures. The NOAEL is 
the highest tested dose at which no statistically 
or biologically adverse effects can be identi­
fied, and is used in regulatory toxicology as 
a point of departure for establishing “accept­
able” exposures for humans.
In experiments with rats, the combined 
effects of anti androgens that act through similar 
mechanisms, such as several phthalates that sup­
press testosterone synthesis (Howdeshell et al. 
2008) or some AR antago nists (Christiansen 
et al. 2008; Hass et al. 2007; Metzdorff et al. 
2007), were additive and could be predicted 
well from the effects of the individual mixture 
components. In addition, combination effects 
were observed at NOAELs for the individual 
chemicals. Less obvious is how combinations 
of anti androgens behave to disrupt androgen 
action via different mechanisms. In the pres­
ent study we investigated the predictability of 
the combined effects of mixtures composed of 
dis similarly acting anti androgens. In pursuing 
this aim, we decided to combine all chemi cals 
in the mixture in proportion to their NOAELs 
for effects on male sexual development. This 
was done in order to investigate whether com­
bination effects occur at individual doses of the 
compounds that are of regulatory relevance, 
and in order to avoid the testing situation in 
which one or two chemicals contribute dispro­
portionately to an overall combination effect. 
Our motivation was not to model environmen­
tal intakes. A second goal was to test whether 
combination effects occur at doses around the 
NOAELs for the single chemicals; this also 
forced us to combine the anti androgens in pro­
portion to their relative potency rather than 
their environmental exposures.
Materials and Methods
Chemicals. We obtained vinclozolin (CAS 
no. 50471­44­8; purity 99%), finasteride 
(CAS no. 98319­26­7; purity 99.8%), DEHP 
(CAS no. 117­81­7; purity 99%), and pro­
chloraz (CAS no. 67747; purity 99.6%) from 
VWR­Bie & Berntsen (Herlev, Denmark). 
The chemicals were dissolved in corn oil (used 
as vehicle) from VWR­Bie & Berntsen.
Animals and dosing. Time­mated nulli­
parous, young adult Wistar rats [HanTac:WH; 
Taconic Europe, Ejby, Denmark; body weight 
(bw) ~ 200 g] were supplied at day 3 of preg­
nancy. The day after mating was designated 
gestational day (GD) 1, and postnatal day 
(PND) 0 was the day of birth. On the day 
after arrival at our facilities (GD4), the dams 
were randomly distributed into groups of 
16 or 8 animals with similar distributions. 
A complete rodent diet for growing ani­
mals (Altromin 1314; soy­ and alfalfa­free; 
Altromin GmbH, Lage, Germany) and acidi­
fied tap water (to prevent microbial growth) 
was provided ad libitum.
Test chemicals and mixtures were adminis­
tered to the dams by gavage from GD7 to the 
day before expected birth (GD21) and from 
PND1 until PND16 (Figure 1), in a dos­
ing volume of 2 mL/kg bw. The dose levels 
and group sizes are shown in Table 1. We 
performed the studies using an experimental 
randomized design of 4 blocks (with 1 week 
between) and implemented in each block the 
same dose regime and number of dams. 
Studies and dose levels. Before conducting 
the mixture experiment, we performed dose–
response studies for each individual chemical. 
The dose ranges were chosen with the aim of 
covering the entire range of responses, from 
no apparent effects to complete feminization, 
as determined by measurements of AGD and 
nipple retention (NR). The same approach 
was used in our first mixture study (Hass et al. 
2007). The dose levels selected for the dose–
response studies were based on the reductions 
of AGD and increases of NR reported for vin­
clozolin (Gray et al. 1994, 1999; Hellwig et al. 
2000; Hotchkiss et al. 2002; Shimamura et al. 
2002), finasteride (Bowman et al. 2003; Clark 
et al. 1990; Hib and Ponzio 1995), DEHP 
(Gray et al. 2000; Jarfelt et al. 2005; Wolf 
et al. 1999), and prochloraz (Laier et al. 2006). 
To gain information about the variability of 
effects between studies, as well as to facili­
tate a direct comparison within the mixture 
study, selected doses of vinclozolin, finasteride, 
DEHP, and prochloraz were run in parallel 
with the mixture experiment.
Two or three selected doses of the four 
chemicals were administered in parallel with 
Figure 1. Outline of the study design adopted for dose–response analyses of anti androgens and their 
mixtures. Mated dams were dosed from GD7 to PND16. Male offspring were examined for multiple signs of 
disrupted sexual development, including AGD on PND0, retained nipples (PND13), weights of prostate and 
LABC (PND16), and malformations of the genital organs (PND16, PND47).
GD7 Dosing PND16
Dam
Male
offspring
Birth
AGD
PND0
Retained nipples
PND13
Organ weights and
malformations
PND16
Malformations
PND47
Table 1. Studies, groups, doses, and number of time-mated animals per group.
Study Treatment groups and doses (mg/kg/day)
No. mated 
(no. pregnant)
Vinclozolin dose–response and prochloraz 
range finding
Control: 0 (vehicle) 16 (13)
Vinclozolin: 5, 10, 20, 40, 80, or 160 8 (6–8)
Prochloraz: 50 or 150 8 (6–8)
Finasteride and DEHP, dose response Control: 0 (vehicle) 16 (15)
Finasteride: 0.001, 0.01, 0.1, 1, 10, or 100a 8/10 (7–9)b
DEHP: 10, 30, 100, 300, 600, or 900 8 (6–8)
 Prochloraz and DEHP, dose response Control: 0 (vehicle) 16 (15)
Prochloraz: 5, 10, 25, 50, or 100 8 (5–8)
DEHP: 3, 10, 30, or 100 16/8 (14/6–8)c
Mixture study of vinclozolin, finasteride, 
DEHP, and prochloraz, 5:0.01:3:5 ratio
Control: 0 (vehicle) 16 (13)
Mixture: 13.01, 65.05, or 130.10 16 (11–16)
Vinclozolin: 5d or 50e 8 (7–8)
Finasteride: 0.01d or 0.1e 8 (6)
DEHP: 3,d 15,f or 30e 8 (5–7)
Prochloraz: 5,d 25,f or 50e 8 (6–7)
aDose induced perinatal death and low pup weight and had to be decreased to 50 mg/kg bw/day from PNDs 1–3 (block 1), 
from GD18 (block 2), and from GD11 (block 3); in block 4 the dams received 50 mg/kg bw/day during the whole dosing 
period. We used 50 mg/kg bw/day for data analysis. bThe finasteride dose group had 10 time-mated animals, whereas 
all other dose groups had 8. cBecause the 3-mg/kg DEHP dose group was not investigated in other studies, 16 rats were 
mated, compared with 8 in other dose groups. dDose of single chemical present in the 13.01-mg/kg bw/day mixture dose. 
eDose of the single chemical included in the 130.10-mg/kg mixture dose. fDose of the single chemical included in the 
65.05-mg/kg mixture dose. 
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the mixture doses. For the mixture experi­
ment, a master mixture was prepared by 
combining doses of the four chemicals at a 
fixed ratio of 500:1:300:500 (vinclozolin: 
finasteride:DEHP:prochloraz). Thus, the mas­
ter mixture contained 15,000 mg vinclozo­
lin, 30.0 mg finasteride, 9,000 mg DEHP, 
and 15,000 mg prochloraz in 600 mL corn 
oil. The master mixture was administered 
undiluted in a dosing volume of 2 mL/kg 
bw to achieve the highest mixture dose of 
130.1 mg/kg/day. Dilutions of 1:1 and 1:9 
in corn oil were prepared for the two remain­
ing dose groups of 65.05 mg/kg/day and 
13.01 mg/kg/day, respectively. The lowest 
mixture dose was equivalent to the sum of the 
chemicals’ individual NOAELs for retained 
nipples (NR NOAEL), the middle dose was 
5­fold higher, and the highest dose was 10­fold 
this value. The animals were treated humanely 
and with regard for allevia tion of suffering. 
The animal studies were performed under 
conditions approved by the Danish Agency for 
Protection of Experimental Animals and by 
the in­house Animal Welfare Committee of 
the National Food Institute at the Technical 
University of Denmark. 
Determination of changes in male sexual 
differentiation. AGD and NR. In all studies, 
AGD and NR were recorded by the same tech­
nician who was blinded with respect to expo­
sure groups. After birth (PND0), all live pups 
in the litter were weighed and sexed, and AGD 
was meas ured using a stereo microscope. We 
transformed the crude AGD measurements to 
the AGD index by dividing AGD by the cube 
root of body weight. The cube root was used 
because this method allowed us to convert a 
three­dimensional end point (weight) into a 
one­dimensional end point (AGD) (Gallavan 
et al. 1999; Wolf et al. 1999). Using this ratio 
required us to assume that the relationship 
between AGD and transformed body weight 
is directly proportional and linear. To assess 
the validity of this assumption, we explored the 
influence of using the transformed body weight 
as a covariable in statistical analyses. However, 
we found no relevant differences between these 
two approaches. In the interest of keeping the 
model parameters as simple as possible (to avoid 
over parameterization), we decided to base all 
statistical analyses on the AGD index.
The body weights of all pups were recorded 
on PND13, together with the number of nip­
ples/areolas, defined as a dark focal area (with 
or without a nipple bud) located where nip­
ples are normally present in female offspring. 
Females normally have 12 nipples, but may in 
a few cases have up to 14.
Organ weights and assessment of mal-
forma tions in external genitalia. On PND16, 
two to six male pups per litter were weighed and 
their external genitalia were inspected. From 
one male per litter, we excised and weighed 
the following organs: testis, epididymis, ventral 
prostate, seminal vesicles, levator ani/bulbo­
cavernosus muscles (LABC), bulbo urethral 
glands, adrenals, kidney, and liver. In all exam­
ined males, the level of demasculinization was 
scored on a scale from 0 to 3, with the observer 
being blinded with respect to dose group. The 
scores were as follows:
•	Score	0	(no	effect):	The	genital	tubercle	was	
normal, with the urethral opening at the tip 
of the genital tubercle and the pre putial skin 
intact. In the perineal area, thick fur extended 
caudally from the base of the genital tubercle 
and half the distance to the anus. A furless 
area circumscribed the anus.
•	Score	1	(mild	dysgenesis	of	the	external	geni­
tals): A small cavity on the inferior side of the 
genital tubercle or a minor cleft in the prepu­
tial opening was observed (estimated value 
of 0.5–1.4 on an arbitrary scale). The size of 
the genital tubercle was decreased. The furless 
area around the anus expanded toward the 
base of the genital tubercle, but thick fur was 
still present at the base of the genital tubercle.
•	Score	2	(moderate	dysgenesis	of	the	external	
genitals): The preputial cleft was larger (esti­
mated value of 1.5–2.4 on an arbitrary scale). 
The urethral opening was situated half way 
down toward the base of the genital tubercle 
(hypospadias). Partly furless areas or thin fur 
was noted in the perineal area extending from 
the base of the genital tubercle and caudally 
to the furless area circumscribing the anus.
•	Score	3	(severe	dysgenesis	of	 the	external	
genitals): The preputial cleft was large (esti­
mated value of 2.5–3.5 on an arbitrary scale). 
The urethral opening was situated farther 
than half way down the inferior side of the 
genital tubercle to the base of the genital 
tubercle (hypospadias). At the base of the 
genital tubercle, a groove extended laterally 
(similar to females on PND16). The male 
was totally furless in the entire perineal area.
For data analysis, we simplified the scoring 
into a binary variable, with scores 0 and 1 (no 
cleft phallus) versus scores 2 and 3 (clear and 
marked cleft phallus).
One male per litter was held after wean­
ing in order to examine the external repro­
ductive organs after sexual maturation. On 
PND47, malformations and changes of the 
external male reproductive organs, including 
cleft phallus/hypospadias and blind vaginal 
opening, were scored by the same technician, 
again blinded with respect to exposure groups. 
The changes were scored on a scale from 0 
to 3 using the follow ing criteria: 0, normal 
external reproductive organs; 1, slight cleft or 
variations of preputium but no hypospadias 
or blind vaginal opening; 2, clear hypospa­
dias but no blind vaginal opening; 3, marked 
hypospadias with visible os penis and blind 
vaginal opening. For data analysis, we trans­
formed the scoring into a binary variable, with 
scores 0 and 1 (no hypospadias) versus scores 
2 and 3 (clear and marked hypospadias).
Data normalizations. To enable pooling of 
the data from our studies, which in some cases 
stretched over a period of 3 years, all regres­
sion analyses had to be based on normalized 
values. For organ weight data from PND16, 
we found a linear relationship between organ 
weights and body weight, based on all con­
trol pups, with the corresponding regression 
lines going through the origin within their 
95% confidence belts. Therefore, individual 
organ weights were normalized to the ratio 
between that organ weight and body weight. 
Furthermore, we controlled for slight differ­
ences in control values between studies by stan­
dardizing these ratios to 1 by dividing them 
through the mean normalized organ weight 
from unexposed male pups. In a similar way, 
we standardized the absolute AGD indices to 
relative values between 1 (no effect on male 
AGD index) and 0 (complete feminization). 
The mean AGD indices from unexposed male 
and female pups were used to define the mini­
mum and maximum responses, respectively. 
Assessment of NR yielded count values, which 
were used without further normalization. Data 
normalizations were also not necessary in the 
case of the binary malformation scores.
Dose–response analyses. By using Shapiro­
Wilk’s and Bartlett’s tests, we confirmed that 
all continuous effect measurements were nor­
mally distributed and homogeneous. Responses 
different from controls were assessed for statis­
tical significance by multiple testing methods 
(global error rate α = 5%, two­sided). Statistical 
analyses were always adjusted for litter effects 
by using litter as an independent, random, and 
nested factor; statistical significance was then 
assessed on the basis of multiple contrast tests 
(for additional details, see Hass et al. 2007). 
When organ weights were analyzed, body 
weight was included as covariate.
Statistical dose–response regression analy­
ses were conducted in the same way for the 
mixture and the single compounds, with 
analyses for the single compounds based on 
pooled effect data from initial dose–response 
studies and the repeated doses that were run 
concurrently with the mixture study [see 
Supplemental Material, Tables 1 and 2, avail­
able online (doi:10.1289/ehp.0900689.S1 
via http://dx.doi.org/)]. We used a best­fit 
approach (Scholze et al. 2001), where vari­
ous non linear regression models (logit, probit 
Weibull, generalized logit) were fitted inde­
pendently to the same data set. The best­fitting 
model was selected on the basis of a statistical 
goodness­of­fit criterion [Schwarz information 
criterion (Schwarz 1978)]. To control for litter 
effects, dose–response data were analyzed by 
using a generalized non linear mixed model­
ing approach (Vonesh and Chinchilli 1996), 
with litter as a random effect modifier for 
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individual effect data. The dose–response func­
tions described by Scholze et al. (2001) assume 
mono tonic increasing relationships, but some 
end points studied here yielded monotonic 
decreasing forms. To maintain compatibility 
with the dose–response functions described by 
Scholze et al. (2001), we exchanged the upper 
and lower asymptotes in the regression models; 
that is, the θmax values in the corresponding 
functions of Table 2 were used as θmin, and 
vice versa.
All analyses were carried out using the 
SAS procedures PROC GENMOD, PROC 
MIXED, and PROC MULTTEST (SAS ver­
sion 8; SAS Institute Inc., Cary, NC, USA).
Additional details are published elsewhere 
(Hass et al. 2007; Metzdorff et al. 2007; 
Christiansen et al. 2008). 
Calculation of mixture-effect predictions. In 
making predictions for the combined effects of 
DEHP, vinclozolin, prochloraz, and finasteride, 
we assumed that each chemical in the mixture 
did not exacerbate or diminish the effects of 
the other components. Mixture effects accord­
ing to such “no interaction” or “additivity” 
assumptions can be calculated using two alter­
native concepts, dose addition and independent 
action. Dose addition looks at mixture effects in 
terms of a “dilution principle.” It assumes that 
one chemical can be replaced totally or in part 
by an equal fraction of an equi effective dose of 
another, without diminishing the overall com­
bined effect (Loewe and Muischnek 1926). 
Dose addition is often used for mixtures com­
posed of chemicals that act through a similar 
or common mode of action [COT 2002; U.S. 
Environmental Protection Agency (EPA) 1986, 
2000, 2002]. Its application to the present mix­
ture of four anti androgens appeared justified 
because all chemicals affect the biological action 
of testosterone and DHT during develop­
ment and produce common effect outcomes. 
However, it can be argued with equal justifica­
tion that the similarity assumption charac teristic 
for dose addition is not applicable to the cho­
sen mixture because its component chemicals 
produce their effects by a variety of molecular 
mechanisms. For this reason, we also employed 
the alternative concept of independent action to 
construct additivity expectations. Independent 
action assumes that the joint effects of a combi­
nation of agents can be calculated by adopting 
the statistical concept of independent events 
(Bliss 1939). It is viewed as appropriate for mix­
tures of chemicals with diverse modes of action 
(COT 2002); however, dose addition and inde­
pendent action can yield very similar additive 
mixture­effect predictions at low doses.
Under the assumption of dose­additive 
combination effects, or those conforming 
with independent action, we predicted dose–
response relationships for the mixture with 
a defined mixture ratio (“fixed mixture ratio 
design”; Faust et al. 2001) using the best­fit 
dose–response regression curves of the individ­
ual compounds [see Supplemental Material, 
Tables 1–3 (doi:10.1289/ehp.0900689.S1)] 
and compared them with the observed mix­
ture effects (Supplemental Material, Table 
3). Equation 1 allows the calculation of any 
effect dose of a mixture under the hypothesis 
of dose additivity. For this, the dose–response 
functions of all mixture components and the 
mixture ratios have to be known:
 
,
EDx EDx
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p
EDx
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1 2
3 4
= +
+ +
-
c
m  [1]
where EDx1, EDx2, EDx3, and EDx4 are the 
effect doses of vinclozolin, finasteride, DEHP, 
and prochloraz, respectively, that on their own 
produce the same quantitative effect x as the 
mixture, and p1, p2, p3, and p4 are the relative 
proportions of the corresponding individual 
doses present in the total mixture dose. We 
derived the individual effect doses from the 
dose–response functions for the compounds by 
using their inverse functional form. If no effects 
were observed in the tested dose ranges for the 
ith compound, we replaced the missing infor­
mation about the effect doses in Equation 1 
(EDxi) by assuming either a maximal effect 
(realized mathematically by approximating a 
“yes/no” step function through a dose–response 
logit function with model steepness parameter 
θ2 = 40) or no effect at all (i.e., setting the ratio 
pi/EDxi in Equation 1 to zero) for doses exceed­
ing those that were actually tested. This pro­
cedure had to be adopted in order to calculate 
mixture­effect predictions for genital malforma­
tions, because two of the mixture components, 
DEHP and prochloraz, were without observable 
effects on their own [see Supplemental Material, 
Tables 1 and 3 (doi:10.1289/ehp.0900689.
S1)]. These two extrapolation scenarios define 
the only possible prediction range of mixture 
responses according to Equation 1.
The basic version of independent action has 
been formulated under the simple assumption 
that the susceptibilities of the individuals of an 
at­risk­population to different dissimilarly act­
ing mixture compounds are not correlated with 
each other (Bliss 1939). For a four­component 
mixture this can be defined by 
 E(cmix) = 1 – [1–E(c1)] × [1–E(c2)] 
  × [1–E(c3)] × [1–E(c4)], [2]
where E(c1), E(c2), E(c3), and E(c4) denote 
the fractional effects (x%) caused by the indi­
vidual concentrations c1, c2, c3, and c4 of vin­
clozolin, finasteride, DEHP, and prochloraz, 
respectively, and E(cmix) is the total effect of 
the mixture concentration cmix. The individ­
ual effects of mixture compounds E(ci) are 
estimated from the concentration response 
functions determined for single substances 
(Table 1). Equation 2 cannot be transformed 
into an explicit term for an effect mixture dose 
EDxmix, but the value of EDxmix satisfying 
Equation 2 for a given effect level x has to be 
computed by an iterative procedure. The sta­
tistical uncertainty for the predicted mixture 
effects and effect doses was determined using 
Table 2. Statistical uncertainty of predicted and observed effect doses for the mixture of DEHP, vinclozolin, 
prochloraz, and finasteride.
Effect doses for the mixture (mg/kg/day)
Observeda Predicted by DA Predicted by IA 
Effect level Mean (95% CI) Mean (95% CI) Mean (95% CI)
Relative AGD index
90% 11.8 (4.3–34.7) 12.2 (0.3–53.8) 12.3 (0.2–58.2)
60% 77.1 (59.4–99.8) 195.6 (147.2–262.3)* 214.3 (179.2–250.6)*
No. of nipples/areolas
3 10.6 (6.5–15.3) 8.8 (5.6–13.6) 6.7 (4.1–13.5)
6 23.3 (17.0–29.4) 25.8 (16.8–35.7) 25.1 (16.8–41.4)
Organ weights in relation to the controls
Ventral prostate (mg)
90% 44.7 (13.9–79.3) 44.6 (6.2–65.2) 24.4 (0.1–68.6)
60% 103.7 (78.9–130.5 162.1 (128.6–226.5) 148.4 (98.4–200.8)
LABC (mg)
90% 51.0 (19.3–81.9) 48.1 (3.5–78.3) 25.9 (0.02–93.1)
60% 118.9 (93.9–152.1) 179.7 (142.8–325.3) 176.2 (109.1–252.8)
Likelihood for malformation at PND16 (cleft phallus)
10% 25.5 (21.0–31.2) 96.5–133.1b* 140.0–140.1b*
50% 37.5 (32.6–44.6) 149.1–226.2b* 226.2–226.4b*
Abbreviations: DA, dose addition; IA, independent action. Predicted effect doses are based on pooled data from studies 
for vinclozolin, prochloraz, finasteride, and DEHP and were calculated from the respective dose–response functions 
given in Supplemental Material, Table 2 (doi:10.1289/ehp.0900689.S1).
aEffect doses as calculated from the dose–response functions given in Supplemental Material, Table 2 (doi:10.1289/
ehp.0900689.S1). bNo pups with malformations were observed for the tested doses of DEHP and prochloraz. For this 
reason, the calculation of expected mixture effect was based on two conjectures: For doses exceeding the tested dose 
range, we assumed either that effects were absent or that they reached maximal response. These two worst-case 
extrapolations define the only possible range of effects and were used to calculate the predicted effect doses for the 
mixture. *Statistically significant compared with observed effect doses. 
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the bootstrap method (Efron and Tibshirani 
1993) and expressed as 95% confidence limits 
for the predicted mean estimate. Differences 
between predicted and observed effect doses 
were deemed statistically significant when the 
95% confidence belts of the prediction did 
not overlap with those of the experimentally 
observed mixture effects.
Results
Dose–response analyses with the individual 
mixture components. Of all indicators of dis­
rupted sexual development, alterations in 
retained nipples were the most sensitive end 
point, with effects becoming noticeable at the 
lowest doses. Changes in AGD were almost as 
sensitive, followed by reductions in prostate, 
LABC weights, and genital malformations. 
Finasteride was by far the most potent chemi­
cal. It exhibited dose–response curves with very 
shallow gradients for all end points. Vinclozolin 
was active in a narrower dose range, with corre­
spondingly steeper dose–response curves, and 
the characteristics of prochloraz and DEHP fell 
between these extremes. Details of the dosing 
schedules and the timing of the various stud­
ies are presented in Table 1. A summary of 
dose–response descriptors for all tested chemi­
cals, based on the pooled outcome of studies 
conducted before the mixture experiment, is 
available in Supplemental Material, Tables 1–3 
(doi:10.1289/ehp.0900689.S1); responses seen 
with individual chemicals tested in parallel 
with the mixture are described in Supplemental 
Material, Table 4.
Prediction of mixture effects. The mix­
ture ratio used in our study was chosen to 
reflect the NOAELs of each chemical alone, 
judged in relation to the most sensitive indi­
cator of disruption of male sexual develop­
ment, increased NR. These NOAELs, here 
referred to as NR NOAELs, were estimated in 
our laboratory before the mixture experiment 
began (3 mg/kg/day for DEHP, 5 mg/kg/day 
for vinclozolin, 5 mg/kg/day for prochloraz, 
and 0.01 mg/kg/day for finasteride). Our NR 
NOAELs agree well with the doses that are 
currently used as starting points for estab­
lishing tolerable exposures for humans [see 
Supplemental Material, Table 5 (doi:10.1289/
ehp.0900689.S1)]. We tested mixture doses 
equal to the sum of NR NOAELs (13.01 mg/
kg/day) and multiples of 5 (65.05 mg/kg/day) 
and 10 (130.1 mg/kg/day). 
Additive mixture effects. Figure 2 shows 
how the experimentally observed responses 
compared with the additive effects of the mix­
ture that were predicted using dose addition. 
The effect outcomes of the mixture experiment 
are available in Supplemental Material, Table 4 
(doi:10.1289/ehp.0900689.S1). Changes in 
AGD, retained nipples, prostate weights, and 
weights of LABC were chosen as the end points 
for evaluation. In all cases, the overall effect 
means measured for all litters came close to the 
predicted response curves. We found consider­
able overlap between the mean responses for 
individual litters and the anticipated effects. 
To evaluate the relationship between predic­
tions and observations statistically, we used the 
effect variability seen with the single chemicals 
to estimate statistical confidence limits for the 
predicted (dose­additive) effect doses by apply­
ing boot strapping methodology. A statistically 
significant difference between anticipated and 
observed effect dose could not be detected, 
except for doses that caused changes in AGD 
at an effect level of 60% change relative to 
controls (Table 2). The mixture­effect doses 
predicted using the alternative concept of inde­
pendent action did not differ significantly from 
those anticipated by dose addition. For all end 
points, the observed mixture effects were stron­
ger than the responses attributable to any one 
single mixture component. Our data suggest 
that the combined effects of DEHP, vinclo­
zolin, prochloraz, and finasteride are additive 
when the evaluation is based on changes in 
AGD, retained nipples, prostate weights, and 
weights of LABC.
Synergistic effects for genital malforma-
tions. Strikingly, a completely different pic­
ture emerged when we evaluated dysgenesis 
of the external genitalia in young male rats at 
PND16 and PND47. Administration of the 
mixture led to severe malformations at PND16 
characterized by enlarged pre putial clefts, and 
urethral openings located toward the base of 
the genital tubercle (not at its top, as normally 
expected), similar to hypospadias in humans. A 
laterally extending groove resembling a vaginal 
opening was often found at the base of the 
genital tubercle. The number of males affected 
by these abnormalities at PND16 was scored 
and expressed as likelihood for severe mal­
formations [Figure 3; see also Supplemental 
Material, Table 4 (doi:10.1289/ehp.0900689.
S1)]. Milder signs of genital dys genesis—such 
as small cavities appearing on the inferior side 
of the genital tubercle, minor clefts in the 
preputial opening, or small genital tubercles—
were not taken into account. At the lowest 
tested mixture dose, none of the effects classed 
as severe malformations were noted. At the sec­
ond highest mixture dose, 26% of the animals 
were affected; at the highest tested mixture 
dose, virtually all animals (94%) showed severe 
malformations. Similar malformation rates for 
hypospadias, including exposure of the os penis 
and blind vaginal opening, became apparent 
at PND47. At the doses included in the mix­
ture, none of the chemicals alone induced mal­
formations, with the exception of vinclozolin 
at 50 mg/kg/day, where a low frequency was 
observed [see Supplemental Material, Table 4 
(doi:10.1289/ehp.0900689.S1)].
Based on the dose–response data for the 
individual chemicals [pooled data from all 
Figure 2. Prediction and assessment of combination effects of anti androgens with mixed modes of action 
on hallmarks of male sexual development in rats exposed gestationally to a combination of DEHP, vinclo-
zolin, prochloraz, and finasteride with a mixture ratio of 3:5:5:0.01. Doses shown are total mixture doses. 
(A) Changes in anogenital index at PND1. (B) Weight changes of the LABC at PND16 normalized in relation 
to body weight and untreated controls. (C) Number of retained nipples at PND13. (D) Weight changes of 
ventral prostates at PND16 normalized to body weight and untreated controls. The predicted mixture effects 
were derived by using dose addition. Error bars for group means indicate SEM. 
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studies (Table 1) and tests conducted con­
currently with the mixture experiment], we 
calculated the probability for malformations at 
PND16 according to dose addition and inde­
pendent action. We found that both of these 
concepts underestimated the observed effects 
by a considerable margin (Figure 3). Because 
DEHP and prochloraz on their own were 
without detectable effects at doses between 
3 and 30 mg/kg/day and 5 and 50 mg/kg/
day, respectively, we based the calculation of 
combination effects according to dose addi­
tion on two conjectures: We assumed either 
that DEHP and prochloraz did not contrib­
ute to the overall combination effect, or that 
their individual effects approached 100% as 
the doses increased beyond the tested range. 
These two assumptions define the extremes 
of the dose addition prediction area shown 
in Figure 3. The independent action predic­
tion yielded a curve that was congruent with 
the high­dose extreme of the dose addition 
prediction area. Malformations occurred at 
3­fold lower mixture doses than predicted by 
both of these models (Figure 3; Table 2). The 
steepness of the under lying dose–response 
curve indicates that a dose anticipated as 
being without effect produced malformations 
in 94% of the animals. Evaluated in relation 
to the low­dose margin of the dose­addition 
prediction area, the mixture caused malfor­
mations at 2­fold lower doses. The experi­
mentally observed responses clearly exceeded 
the predictions, suggesting that the combined 
effect of DEHP, vinclozolin, prochloraz, and 
finasteride is synergistic with respect to genital 
malformations.
Combination effects at doses around 
NOAELs. Next, we tested the idea that mix­
ture effects should not occur when mixed­
mode chemicals are combined at dose levels 
close to those used as points of departure in 
regulatory toxicology for the estimation of 
safe human exposures, such as NOAELs. 
DEHP, vinclozolin, prochloraz, and finas­
teride were combined at doses equal to their 
individual NR NOAELs for changes in NR 
that were estimated in studies preceding the 
mixture experiment. At these doses, none of 
the individual chemicals on their own pro­
duced changes in AGD, yet the combination 
induced a statistically significant effect, well 
predicted by dose addition and independent 
action. At 10­fold higher doses, the effects 
of vinclozolin and finasteride alone (but not 
DEHP and prochloraz) reached statistical 
significance. At this point, the combination 
strongly exacerbated the response, with AGD 
halfway between those expected in normal 
males and normal females (Figure 4A).
With weight changes of the prostate and 
LABC as the end points for assessment, the 
NR NOAEL combination did not produce 
effects distinguishable from untreated con­
trols. When tested in parallel with the mix­
ture, finasteride on its own yielded statistically 
significant responses for NR at its previously 
estimated NR NOAEL of 0.01 mg/kg/day. 
This prevented us from conducting the above 
analyses in relation to retained nipples.
Combined at their NR NOAELs, the four 
anti androgens did not provoke appreciably 
elevated malformation rates, but the 5­fold 
higher mixture dose induced malformations 
in approximately 25% of the males. At this 
point, none of the single chemicals alone is 
likely to have led to observable malformations 
[Figure 3; see also Supplemental Material, 
Table 4 (doi:10.1289/ehp.0900689.S1)]. 
Even at the levels present in the 10­fold higher 
mixture dose, three of the single chemi cals 
alone did not induce discernable effects, but 
vinclozolin on its own caused malformations 
in about 5% of the affected males. Yet, when 
combined at the doses equivalent to 10­fold 
NR NOAELs, we observed mal formations in 
nearly all male offspring (Figure 4B). Similar 
results became apparent when malformations 
were analyzed later in the rats lives, at PND47 
(Figure 4C).
Discussion
In relation to certain sensitive hallmarks of 
disrupted male sexual differentiation, dose 
addition and independent action proved to 
be equally useful tools for the prediction of 
combination effects of mixed­mode anti­
androgens. For alterations in AGD, retained 
nipples, and weight changes in prostate and 
LABC, reasonable anticipations of mixture 
effects could be achieved on the basis of dose–
response descriptors for the individual mixture 
components. That this occurred despite the 
different mechanistic premises that underlie 
the two prediction concepts is coincidental. 
It is explained not by toxicologic features but 
by the mathematical algorithms behind each 
concept (Drescher and Bödeker 1995). Our 
results hold the promise that predictions of 
combination effects could be obtained in the 
future without conducting mixture experi­
ments but by employing modeling approaches. 
Considering the high cost and long duration 
of reproductive toxicity studies, this might 
greatly aid efforts in regulatory toxicology.
All the more remarkable are our observa­
tions of synergistic interactions with genital 
malformations such as hypospadias. Because 
the affected males derived from dams that 
were dosed in the same way as those where 
additive effects on characteristics of dis­
rupted sexual development were found, dos­
ing errors cannot account for the deviations 
from expected additivity. Assessment errors 
introduced during the scoring of the mal­
formations, leading to the detection of false 
positives, are also not a likely explanation, 
because we disregarded the milder forms of 
malformations that may be difficult to diag­
nose. The fact that finasteride, when tested 
concurrently with the mixture, proved to be 
more effective in inducing retained nipples 
than seen previously also does not explain 
the synergism. We found no changes in the 
chemicals’ effectiveness of causing malforma­
tions. As with the other end points used in 
this study, androgens are key factors for the 
normal development of the penis from the 
genital tubercle. The observed malformations, 
including hypospadias, indicate disruption of 
androgen action. This leads to a failure of the 
folding and fusion that needs to take place 
during develop ment to form normal geni­
tals. Judged from this viewpoint, the mixture 
would be expected to induce additive effects 
on malformations, too. Although we are 
unable to offer a mechanistic explanation for 
the synergisms, it seems that genital develop­
ment in the rat is also governed by events that 
differ in important details from those operat­
ing during the regression of nipple anlagen 
and the formation of normal AGD. Genital 
tubercle development generally also includes 
embryonic processes requiring embryonic cell 
movements and apposition of the two advanc­
ing tissues (Gupta and Goldman 1986).
Recent studies suggest a previously 
unidentified role for the progesterone recep­
tor, possibly interacting with the AR, in 
disturbed genital tubercle develop ment 
(Willingham et al. 2006). In utero exposure to 
natural or synthetic progesterones can increase 
the risk of hypospadias in male mice, and 
Figure 3. Synergistic effects on induction of geni-
tal malformations on PND16 in male rats exposed 
gestationally to combinations of DEHP, vinclozolin, 
prochloraz, and finasteride with a mixture ratio of 
3:5:5:0.01. Doses shown are total mixture doses. 
Genital malformations include enlarged preputial 
clefts and urethral openings located toward the 
base of the genital tubercle, similar to hypospadias 
in humans. Black circles indicate the mean likeli-
hood of malformation, based on 10–15 litters per 
group, with 95% confidence intervals; the solid blue 
line is the best-fit regression model (Weibull) with 
the 95% confidence belt (dashed blue lines); the 
green curve and green shaded area indicate the 
lower and upper estimates of combination effects 
according to dose addition; and the gray curve 
represents combined effects predicted by using 
independent action. 
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intake during pregnancy in humans has been 
associated with increased risks of hypospadias 
(Carmichael et al. 2005; Willingham et al. 
2006). Prochloraz, one of the chemicals in 
the mixture, was able to induce increased tes­
ticular progesterone concentrations in male 
rat fetuses; this effect occurred at lower dose 
levels than those present in the mixture inves­
tigated here (Blystone et al. 2007; Laier et al. 
2006; Vinggaard et al. 2005). Thus, elevated 
progesterone levels due to prochloraz expo­
sure may have a role in the synergisms with 
severe hypospadias that we observed in our 
study. Generally, synergisms may be caused 
by toxico kinetic interactions, where because 
of interference with uptake or metabolism, 
one or several mixture components are pres­
ent at levels higher than would occur if these 
chemicals were given individually. However, 
we regard toxico kinetic interactions as an 
unlikely explanation, because we found dose 
additivity for all other hallmarks of male sex­
ual disruption, including end points assessed 
around or at the same developmental age as 
the genital malformations.
Our findings echo the observations made 
by Rider et al. (2008) where a mixture of 
butyl benzyl phthalate, di­n­butyl phthalate, 
DEHP, vinclozolin, procymidone, linuron, 
and prochloraz induced frequencies of hypo­
spadias that exceeded those predicted by dose 
addition. As in our study, other end points 
that were investigated simultaneously revealed 
dose­additive effects. Rider et al. (2008) used 
historical data for the calculation of additivity 
expectations. Because these data were some­
times based on dosing regimens that differed 
from those used in the mixture experiments, 
there is a degree of uncertainty as to whether 
the excess malformations in that study rep­
resent a true synergism. Our evaluations are 
based on dose–response data for single chemi­
cals and mixtures from one large study and 
therefore substantiate concerns about the syn­
ergistic induction of genital malformations by 
antiandrogens with mixed modes of action.
The effects seen in the rat are of high rele­
vance to the human and deserve serious con­
sideration in ongoing risk assessment efforts. 
Very recently, changes in AGD (Swan et al. 
2005) and suppressions of androgen synthesis 
have been associated with anti androgen expo­
sure in humans (Main et al. 2006).
A point that requires careful consideration 
is whether additive or even synergistic effects 
between anti androgens are also likely to occur 
at low, environmentally relevant exposure 
levels. Human intakes of DEHP alone are 
estimated to be about 1,000 times lower than 
used in our study (National Research Council 
2008), and similar low exposures can be 
expected for the other chemicals that we used. 
It is clear that our developmental rat model 
would not have produced any responses if 
we had combined all mixture components at 
such low levels. However, human populations 
are not just exposed to four antiandrogens, 
but to a larger, although poorly defined num­
ber of chemicals with a potential to interfere 
with androgen action. Under dose addition, 
theory predicts that all these chemicals, even 
at low levels, act together to produce com­
bined effects (Kortenkamp et al. 2007). 
Whether this effect will become observable in 
human populations depends on the number 
of chemicals, their levels, and the sensitivity of 
humans relative to the rat.
Conclusions
Our findings contradict the widely held view 
(COT 2002; VKM 2008) that chemical mix­
tures exhibiting varied modes of action are with­
out combination effects at levels near supposed 
dose thresholds, used in regulatory toxicology as 
points of departure for the derivation of toler­
able human exposures. Were this assumption 
Figure 4. Combination effects in male rats after gestational exposure to low doses of vinclozolin (VZ; 5 mg/
kg/day), finasteride (FIN; 0.01 mg/kg/day), prochloraz (PZ; 5 mg/kg/day), and DEHP (3 mg/kg/day). Doses NR 
NOAELs (left) and 10× NR NOAELs (right). See “Materials and Methods” for details on predicted values for 
dose addition (DA) and independent action (IA). Male offspring were evaluated for changes in AGD (A) and 
genital mal formations at PND16 (cleft phallus; B) and at PND47 (hypospadias; C). Error bars are 95% confi-
dence intervals. The light green part of the bar in B indicates the lower and upper estimates of combination 
effects according to dose addition. 
*Statistically significant compared with controls. 
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correct, we should not have observed altera­
tions in AGD when all four chemicals were 
combined at their NR NOAELs. Despite the 
synergism that we detected, the NR NOAEL 
combination did not produce appreciably 
elevated malformation rates, but this may be 
due to the lower sensitivity of this end point. 
It is likely that a mixture composed of a larger 
number of anti androgens would have produced 
malformations at correspondingly lower doses, 
approaching NR NOAELs. Our observations 
show that the use of NOAELs as points of 
departure in risk assessment may lead to under­
estimations of risk when exposure is to several 
anti androgens with common effect outcomes, 
regardless of mechanism. This highlights the 
deficiencies of the predominant chemical­by­
chemical approach in risk assessment. It is nec­
essary to supplant current procedures by moves 
toward accounting for mixture effects, and our 
results underscore the importance of such a 
paradigm change.
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